BPC-157

Clinical evidence summary

BPC-157, a synthetic peptide derived from human gastric juice, is currently not approved by the U.S. Food and Drug Administration (FDA) for any medical use. As of 2026, it is categorized as a Category 1 compoundable substance in the United States, meaning it can be compounded by licensed pharmacies for individual patient prescriptions, but this does not constitute FDA approval for general marketing or widespread therapeutic use. In Canada, BPC-157 is considered a research-only compound.

The majority of evidence regarding BPC-157's potential therapeutic effects comes from preclinical studies, primarily conducted in in vitro settings and animal models, particularly rodents. These studies suggest several potential mechanisms of action that could contribute to its observed effects. These include promoting angiogenesis (the formation of new blood vessels), upregulating growth hormone receptors, modulating nitric oxide (NO) pathways, and influencing the FAK-paxillin signaling pathway, which is involved in cell adhesion and migration.

In preclinical literature, BPC-157 has been investigated for its potential to aid in the healing of various tissues, including tendons, ligaments, and the gastrointestinal tract. For instance, studies in rodents have explored its effects on accelerating the healing of bone fractures, muscle injuries, and tendon-to-bone healing. Its potential to protect and repair the gastric mucosa has also been a subject of research, with findings suggesting it may mitigate damage caused by certain irritants and promote ulcer healing.

While these preclinical findings are promising, it is crucial to acknowledge the significant gap between the data generated in animal models and human clinical outcomes. There is limited human clinical evidence to support the efficacy and safety of BPC-157 for therapeutic purposes. The use of BPC-157 by athletes and individuals seeking to accelerate healing often relies on anecdotal reports and extrapolations from preclinical research, rather than well-controlled human trials. Therefore, any consideration of BPC-157 should be approached with caution, recognizing that its therapeutic benefits in humans are not yet established through rigorous clinical investigation.

Established dosing protocols

There are no established, FDA-approved dosing protocols for BPC-157. Dosing information that exists is derived from preclinical studies and anecdotal reports, and should not be considered standard medical practice. In preclinical research, doses have varied widely depending on the study design, the animal model used, and the specific condition being investigated. For example, doses in rodent studies have ranged from micrograms to milligrams per kilogram of body weight.

Individuals who choose to use BPC-157, often under the guidance of compounding pharmacies or alternative health practitioners, may encounter a range of suggested dosages. These are typically expressed in micrograms (mcg) or milligrams (mg) per administration, with frequency varying from daily to multiple times per day. Common routes of administration reported in non-clinical contexts include oral, subcutaneous injection, intramuscular injection, and topical application.

It is important to reiterate that these are not evidence-based dosing guidelines for human use. The lack of standardized clinical trials means that optimal dosage, frequency, and duration of treatment for any potential indication in humans are unknown. Any use of BPC-157 should be discussed with a qualified healthcare professional who can assess individual circumstances and potential risks, while also acknowledging the experimental nature of this compound.

Safety profile and contraindications

The safety profile of BPC-157 in humans is not well-established due to the limited clinical research. Preclinical studies have generally reported a good safety profile in animal models, with few observed adverse effects even at relatively high doses. However, extrapolating these findings directly to humans is not scientifically sound.

Potential contraindications for BPC-157 are not definitively known. Given its mechanism of action, which involves promoting growth and healing, caution may be warranted in individuals with certain conditions. For example, individuals with active cancer or a history of certain types of tumors might theoretically be at risk, as peptides that promote cell growth could potentially stimulate the proliferation of cancerous cells. However, this is speculative and not supported by direct clinical evidence in humans.

Individuals with known sensitivities or allergies to peptides or any components used in compounding BPC-157 should avoid its use. Pregnant or breastfeeding women are also typically advised against using unapproved substances due to the unknown risks to the fetus or infant.

Anyone considering the use of BPC-157 should engage in a thorough discussion with a healthcare provider to weigh the potential risks against any perceived benefits, especially in the absence of strong safety data.

Drug interactions and precautions

Specific drug interactions involving BPC-157 have not been systematically studied in humans. Due to its potential effects on healing and cellular processes, theoretical interactions with other medications cannot be ruled out.

For instance, medications that affect blood clotting or wound healing might theoretically interact with BPC-157. If BPC-157 does indeed promote angiogenesis and tissue repair, it could potentially influence the efficacy or side effects of drugs used to manage cardiovascular conditions or wound healing processes. Similarly, immunosuppressants or medications that modulate the immune system could potentially interact with a peptide that influences cellular signaling pathways.

Precautions should be taken by individuals taking any prescription or over-the-counter medications, as well as herbal supplements. It is essential to inform any healthcare provider about the use of BPC-157 to allow for a comprehensive assessment of potential risks. Due to the lack of clinical data, a conservative approach is recommended, and co-administration with other medications should be carefully considered and ideally discussed with a medical professional.

Monitoring during therapy

Given that BPC-157 is not an approved therapy, there are no established clinical monitoring protocols. In the context of its use through compounding pharmacies, monitoring would typically be guided by the prescribing practitioner and the individual's specific health status and reasons for use.

If BPC-157 were to be used for conditions related to gastrointestinal healing, monitoring might involve assessing symptoms such as pain, bloating, or changes in bowel habits. For potential musculoskeletal applications, monitoring could include tracking pain levels, range of motion, and functional improvements. However, these are based on the proposed therapeutic targets and not on observed clinical outcomes in humans.

Standard medical monitoring, such as regular blood work to assess organ function (e.g., liver and kidney function tests) and complete blood counts, might be considered by a healthcare provider as a general precaution, especially if the compound is administered systemically. However, there is no specific evidence to suggest that BPC-157 directly impacts these parameters, and such monitoring would be a general safety measure rather than targeted surveillance for known BPC-157-related effects.

Individuals using BPC-157 should be encouraged to report any new or worsening symptoms to their healthcare provider promptly.

Who should NOT use this

Individuals who should not use BPC-157 include those who are pregnant or breastfeeding, as the safety of the compound in these populations has not been evaluated. Similarly, children and adolescents should not use BPC-157 due to the lack of safety data in these age groups and the potential for interference with normal growth and development.

Individuals with a known history of cancer, particularly hormone-sensitive cancers or those where cell proliferation is a concern, should exercise extreme caution or avoid use. This is based on the theoretical concern that peptides promoting cell growth and angiogenesis could potentially influence tumor behavior. However, this is not based on direct evidence of BPC-157 causing or exacerbating cancer in humans.

Anyone with known hypersensitivity or allergic reactions to peptides or other components of compounded medications should refrain from using BPC-157. Patients with significant pre-existing medical conditions, especially those affecting organ systems that could be indirectly influenced by growth or healing processes, should consult with their healthcare provider before considering its use.

Ultimately, due to the experimental nature of BPC-157 and the absence of FDA approval and comprehensive clinical trials, individuals who prioritize treatments with established safety and efficacy profiles should avoid its use. This includes individuals who are seeking definitive medical treatments for diagnosed conditions and require therapies that have undergone rigorous scientific scrutiny and regulatory review.